

Prof. BAŞAK OYAN ULUÇ

Personal Information

Email: Basak.Uluc@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/833>

International Researcher IDs

ORCID: 0000-0002-6623-6273

Yoksis Researcher ID: 33126

Education

Post Doctorate of Medicine, Hacettepe University, Sağlık Bilimleri Enstitüsü, Klinik Onkoloji A.B.D., Turkey 2001 - 2004

Expertise In Medicine, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, Turkey 1997 - 2001

Undergraduate, Hacettepe University, Tıp Fakültesi, Tıp Pr. (İngilizce), Turkey 1990 - 1996

Foreign Languages

English, C1 Advanced

Dissertations

Post Doctorate of Medicine, Diffüz büyük B hücreli lenfomalarda sağkalım ve prognostik faktörler, Hacettepe University, Sağlık Bilimleri Enstitüsü, Klinik Onkoloji A.B.D., 2004

Expertise In Medicine, Opere Evre I-III Meme Kanserlerinde Adjuvan Siklofosfamid-Adriamisin-5-Florourasil (CAF) Kemoterapisi Sonuçları ve Prognozu Etkileyen Faktörler, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2001

Research Areas

Health Sciences

Academic Positions

Professor, Acibadem Mehmet Ali Aydinlar University, School Of Medicine, Department Of Medical Sciences, 2017 - Continues

Professor, Yeditepe University, School Of Medicine, Department Of Internal Medicine, 2012 - 2016

Associate Professor, Yeditepe University, School Of Medicine, Department Of Internal Medicine, 2006 - 2016

Assistant Professor, Yeditepe University, School Of Medicine, Department Of Internal Medicine, 2006 - 2006

Academic and Administrative Experience

Head of Department, Yeditepe University, School Of Medicine, Tibbi Onkoloji, 2008 - 2016

Courses

Undergraduate

Epidemiology and etiology of cancer, Undergraduate, 2024 - 2025, 2023 - 2024, 2022 - 2023, 2021 - 2022, 2020 - 2021
ONCOLOGIC EMERGENCIES, Undergraduate, 2013 - 2014, 2012 - 2013
PRINCIPLES OF CHEMOTHERAPY AND COMPLICATIONS, Undergraduate, 2013 - 2014, 2012 - 2013
LUNG CANCER, Undergraduate, 2013 - 2014, 2012 - 2013
BREAST CANCER, Undergraduate, 2013 - 2014, 2012 - 2013
APPROACH TO THE PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS, Undergraduate, 2013 - 2014, 2012 - 2013
INTRODUCTION TO CLINICAL ONCOLOGY, Undergraduate, 2013 - 2014, 2012 - 2013
COLORECTAL CANCER, Undergraduate, 2013 - 2014, 2012 - 2013
TUMOR MARKERS AND SCREENING METHODS-EARLY DIAGNOSIS IN ONCOLOGY, Undergraduate, 2013 - 2014, 2012 - 2013

Supervised Theses

Oyan Uluç B., Sönmez Ö., Yüksek gradlı glial tümörlerde tanıda ve nükste PD-L1 ekspresyonu değişimi, Expertise In Medicine, H.ŞEYMA(Student), 2016

Oyan Uluç B., Progrese glial tümörlerde mgmt (metil guanin-dna metil transferaz) metilasyonu ve idh (izositrat dehidrojenaz) mutasyonunda değişimin incelenmesi ve prognoza etkisinin araştırılması, Expertise In Medicine, M.AKİF(Student), 2014

Oyan Uluç B., The prognostic relevance of response evaluation to chemotherapy using FDG-PET/CT in patients with advanced stage non-small-cell lung cancer, Post Doctorate of Medicine, Ç.ORDU(Student), 2010

Oyan Uluç B., Acute effects of Palonosetron on ECG parameters in cancer patients., Post Doctorate of Medicine, C.AKOSMAN(Student), 2010

Jury Memberships

Doctoral Examination, Doctoral Examination, Acibadem Mehmet Ali Aydınlar Üniversitesi, May, 2024

Post Graduate, Post Graduate, Acibadem Mehmet Ali Aydınlar Üniversitesi, June, 2023

Doctoral Examination, Doctoral Examination, Acibadem Mehmet Ali Aydınlar Üniversitesi, May, 2023

Associate Professor Exam, Associate Professor Exam, Fırat Üniversitesi, November, 2021

Assistant Professorship Appointment Committee, Appointment Academic Staff, Haliç Üniversitesi, August, 2021

Journal articles indexed in SCI, SSCI, and AHCI

- I. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Kahraman S., Erul E., Gümüşay O., Guven D. C., Aksoy S., Basaran G., Seyyar M., Sahin E., Cabuk D., Bayram E., et al.
Clinical Breast Cancer, 2025 (SCI-Expanded)
- II. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
Kahraman S., Hızal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., BAYRAM E., Gulbagci B., Yasar A., Davarci S. E., et al.
BMC CANCER, no.1, 2024 (SCI-Expanded)
- III. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
Tascı E. S., Oyan B., Soenmez Ö., Mutlu A. U., Atıcı M. M., Sakın A., Oener I., Cinkir H. Y., Eryılmaz M. K., Caglayan D., et al.

- al.
BMC CANCER, vol.24, no.1, 2024 (SCI-Expanded)
- IV. **Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study**
KARCI E., BİLİCİ A., Bayram B., Celayir M., Ozyurt N., OYAN ULUÇ B., Eken A., BAŞARAN G., Demirci U., Kemal Y., et al. CANCERS, no.19, 2024 (SCI-Expanded)
- V. **A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy**
Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Cicin I., Paydas S., Cilbir E., Sakalar T., Uysal M., et al. MEDICINE, vol.103, no.21, 2024 (SCI-Expanded)
- VI. **Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study**
Tascı E. S., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gundogdu Y., Seyyar M., Sahin E., ÇABUK D., Majidova N., Ugurlu I., et al. EXPERT OPINION ON PHARMACOTHERAPY, vol.25, no.4, pp.477-484, 2024 (SCI-Expanded)
- VII. **Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group**
Kaplan M. A., ŞENDUR M. A. N., KAYI CANGIR A., Firat P., Goker E., Kilickap S., OYAN ULUÇ B., Oz A. B., ÖZDEMİR F., ÖZYİĞİT G.
CURRENT PROBLEMS IN CANCER, vol.47, no.6, 2023 (SCI-Expanded)
- VIII. **Validation of bioelectrical impedance analysis in the evaluation of body composition in patients with breast cancer**
Baş D., ARIBAL M. E., VARDARELİ E., SÖNMEZ Ö., OYAN ULUÇ B., Özden B. Ç., Sonkaya A.
Nutrition in Clinical Practice, vol.38, no.4, pp.817-829, 2023 (SCI-Expanded)
- IX. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.**
Kahraman S., Erul E., Seyyar M., Gümüşay Ö., Bayram E., Demirel B. C., Acar O., Aksoy S., Baytemur N. K., Sahin E., et al.
Future oncology (London, England), 2023 (SCI-Expanded)
- X. **Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.**
Karacın C., Oksuzoglu B., Demirci A., Keskkılıç M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.
BMC cancer, vol.23, no.1, pp.136, 2023 (SCI-Expanded)
- XI. **Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study**
Gursoy P., TATLI A. M., Erdem D., Goker E., Celik E., Demirci N. S., Sakin A., Atci M. M., Bayram E., Telli T. A., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, no.2, pp.865-875, 2023 (SCI-Expanded)
- XII. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**
Gurbuz M., Kutlu Y., Akkus E., KÖKSOY E. B., Kose N., Oven B. B., Uluc B., Demiray A. G., Erdem D., Demir B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XIII. **Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement**
Aytaç E., Özer L., Baca B., Balık E., Kapran Y., Taşkın O. C., Oyan Uluç B., Abacıoğlu M. U., Gönenç M., Bölükbaşı Y., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.8, pp.627-663, 2022 (SCI-Expanded)
- XIV. **Coronaphobia: A barrier to ongoing cancer treatment?**
SÖNMEZ Ö., Tezcanlı E. K., Taşçı E. Ş., Kazancı H. B., Altınok A., Toklucu E., Taşçı Y., Aydoğdu Ç., Aydin A. B., Yüce S., et al.
PSYCHO-ONCOLOGY, vol.31, no.7, pp.1178-1185, 2022 (SCI-Expanded)
- XV. **The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally**

- advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.**
Özdemir Ö., Zengel B., Yıldız Y., Oyan Uluç B., Çabuk D., Özden E., Kivrak Salim D., Paydas S., Demir A., Diker Ö., et al. Anti-cancer drugs, 2022 (SCI-Expanded)
- XVI. Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study**
Tascı E. S., Oyan B., Sonmez Ö., Mutlu A. U., Atıcı M. M., Oner I., Cinkir H. Y., Eryılmaz M. K., Balcık O. Y., Paksoy N., et al. JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- XVII. Identifying Knowledge and Practices regarding Cancer Patient Malnutrition: A Survey Study among Oncologists**
SÖNMEZ Ö., Tezcanlı E. K., Bas D., Kazancı H. B., Altinok A., Demir A., OYAN ULUÇ B. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.74, no.7, pp.2392-2399, 2022 (SCI-Expanded)
- XVIII. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.**
Ak N., Ozkan B., Yenigün M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.26, no.3, pp.819-829, 2021 (SCI-Expanded)
- XIX. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Baybek S., Eralp Y., Saip P. M., Guler E. N., et al. Balkan medical journal, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XX. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.**
Demir A., Molinas Mandel N., Paydaş S., Demir O. G., Er Ö., Turhal N. S., Baybek S., Eralp Y., Saip P. M., Güler E. N., et al. Balkan Medical Journal, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XXI. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study**
Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., SAK S., Dilege S., Tanju S., Toker A., et al. JOURNAL OF THORACIC ONCOLOGY, no.10, 2019 (SCI-Expanded)
- XXII. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group**
AYTAÇ E., Aslan F., ÇİÇEK B., Erdamar S., Gurses B., GÜVEN K., Falay O., KARAHASANOĞLU T., Selcukbiricik F., Selek U., et al. TURKISH JOURNAL OF GASTROENTEROLOGY, no.7, pp.584-598, 2019 (SCI-Expanded)
- XXIII. A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with ras-wild metastatic colorectal cancer: A collaborative study by Turkish oncology group (tog)**
Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacioglu B., Oktay E., Erdem D., Arpacı E., Uluc B., Turhal S., et al. Journal of B.U.ON., vol.24, no.1, pp.242-248, 2019 (SCI-Expanded)
- XXIV. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., ÇİÇİN İ., KÖSTEK O., Kaplan M. A., AKSOY S., AKTAŞ B. E., Ozdemir O., Alacacioglu A., et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded)
- XXV. Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
Kılıçkap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al. JOURNAL OF THORACIC ONCOLOGY, no.10, 2018 (SCI-Expanded)
- XXVI. Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic**

- cancer patients to be treated with immune checkpoint inhibitors.**
Oyan B., Sonmez Ö., Yazar A., Teomet M.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXVII. Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
American journal of therapeutics, vol.23, 2016 (SCI-Expanded)
- XXVIII. Is It Time for Maintenance Chemotherapy for Advanced Gastric Adenocarcinoma?**
Eren O., Sönmez Ö., Oyan B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, pp.2067, 2016 (SCI-Expanded)
- XXIX. Bilateral synchronous adrenal metastasis of invasive ductal carcinoma treated with multimodality therapy including adrenalectomy and oophorectomy.**
Eren O., Ordu C., Selcuk N., Akosman C., Ozturk M., Özkan F., Gokce Ö., Oyan B.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.22, pp.157-60, 2016 (SCI-Expanded)
- XXX. May there be a role for hormonal manipulation for treatment of hormone receptor negative breast cancer?**
Onder E., Uysal S., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.1380, 2015 (SCI-Expanded)
- XXXI. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study**
Abali H., ÇELİK İ., Karaca B., TURNA Z. H., KAYTAN SAĞLAM E., Akman T., ÖZTOP İ., COŞKUN H. Ş., Turhal N. S., Sezer A., et al.
JOURNAL OF BUON, vol.20, no.4, pp.1137-1141, 2015 (SCI-Expanded)
- XXXII. Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.**
Akosman C., Ordu C., Eroglu E., Oyan B.
American journal of therapeutics, vol.22, no.3, 2015 (SCI-Expanded)
- XXXIII. Revisiting post-gastrectomy anemia with a brief survey among a group of Turkish medical oncologists.**
Eren O., Sonmez Ö., Ozkan H., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.808-11, 2015 (SCI-Expanded)
- XXXIV. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.**
Ordu C., Selcuk N., Akosman C., Eren O., Altunok E., Toklu T., Oyan B.
Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.321-6, 2015 (SCI-Expanded)
- XXXV. Voltage-gated sodium channel blockers can augment the efficacy of chemotherapeutics by their inhibitory effect on epithelial-mesenchymal transition.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
Medical hypotheses, vol.84, pp.11-3, 2015 (SCI-Expanded)
- XXXVI. Pituitary metastasis of colon adenocarcinoma: a rare occurrence.**
Ozturk M., Eren O., Sarikaya B., Aslan E., Oyan B.
Journal of gastrointestinal cancer, pp.85-7, 2014 (SCI-Expanded)
- XXXVII. Gastric metastasis in a patient with lobular breast carcinoma 6 years after diagnosis.**
Eren O., Ozturk M., Sonmez Ö., Aslan E., Ozkan F., Oyan B.
Journal of gastrointestinal cancer, vol.45, pp.504-5, 2014 (SCI-Expanded)
- XXXVIII. Voltage-gated sodium channel blockade for inhibition of EMT.**
Eren O., Oyan B.
Trends in pharmacological sciences, vol.35, pp.621, 2014 (SCI-Expanded)
- XXXIX. Should we be more cautious about replacement of vitamin B12 in patients with cancer receiving cytotoxic chemotherapy?**

- Eren O., Ozturk M., Sonmez Ö., Oyan B.
Medical hypotheses, vol.83, pp.726-9, 2014 (SCI-Expanded)
- XL. **Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup**
Rordorf T., Hassan A. A., Azim H., Alexandru E., ER O., Gokmen E., Gural Z., Mardiak J., Minchev V., Peintinger F., et al.
BREAST, vol.23, no.5, pp.511-525, 2014 (SCI-Expanded)
- XLI. **Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?**
Eren O., Ozturk M., Oyan B.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol.22, pp.2599-600, 2014 (SCI-Expanded)
- XLII. **Does cetuximab cause small bowel perforation?**
Ozturk M., Eren O., Oyan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.865, 2014 (SCI-Expanded)
- XLIII. **Reply to the letter to the editor 'Are male gender and nonadenocarcinoma histology valid prognostic factors for breast cancer?' by Eren et al.**
Eren O., Ozturk M., Sonmez Ö., Oyan B.
ANNALS OF ONCOLOGY, vol.25, no.4, pp.911, 2014 (SCI-Expanded)
- XLIV. **Gallbladder perforation related to bevacizumab.**
Ozturk M., Kalayci M., Oyan B.
Clinics and research in hepatology and gastroenterology, vol.37, 2013 (SCI-Expanded)
- XLV. **HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.**
Dent S., Oyan B., Honig A., Mano M., Howell S.
Cancer treatment reviews, vol.39, pp.622-31, 2013 (SCI-Expanded)
- XLVI. **Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.**
Ozturk M., Ozveren O., Cinar V., Erdik B., Oyan B.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol.24, pp.90-4, 2013 (SCI-Expanded)
- XLVII. **Why do targeted agents not work in the adjuvant setting in colon cancer?**
Oyan B.
Expert review of anticancer therapy, vol.12, pp.1337-45, 2012 (SCI-Expanded)
- XLVIII. **Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.**
Oyan B.
Medical hypotheses, vol.77, pp.1028-30, 2011 (SCI-Expanded)
- XLIX. **The early metabolic effect of zolendronic acid on FDG-PET scans in patients with bone metastasis**
Selcuk N. A., Uluc B., Akosman C., Ordu C., Toklu T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- L. **The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small-cell lung cancer**
Selcuk N. A., Uluc B., Ordu C., Akosman C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- LI. **Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment.**
Akosman C., Selcuk N. A., Ordu C., Ercan S., Ekici I. D., Oyan B.
Cancer imaging : the official publication of the International Cancer Imaging Society, vol.11, no.1, pp.52-5, 2011 (SCI-Expanded)
- LII. **The acute effects of palonosetron on ECG parameters in patients with cancer**
Akosman C., Ordu C., Oyan B.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LIII. **The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**

- Ordu C., Selcuk N. A., Akosman C., Oyan B.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LIV. **The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**
Ordu C., Selcuk N. A., Akosman C., Oyan B.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (SCI-Expanded)
- LV. **High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
Clinical transplantation, vol.23, pp.839-47, 2009 (SCI-Expanded)
- LVI. **Validation of FDG-PET/CT in evaluation of early remission in patients with refractory lymphoma after treatment with high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)**
Selcuk N. A., Civi G., Toklu T., Oyan B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.36, 2009 (SCI-Expanded)
- LVII. **The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.**
Yavas O., Yazici M., Eren O., Oyan B.
Swiss medical weekly, vol.137, pp.556-8, 2007 (SCI-Expanded)
- LVIII. **Hemorrhagic cystitis due to viral infection following hematopoietic stem cell transplantation**
Obek C., Kocagoz T., Aktas S., Yencilek F., Uluc B., Koc Y.
JOURNAL OF ENDouroLOGY, vol.21, 2007 (SCI-Expanded)
- LIX. **Current medical treatment of pancreatic neuroendocrine tumors**
Yalcin S., Oyan B., Bayraktar Y.
HEPATO-GASTROENTEROLOGY, vol.54, no.73, pp.278-284, 2007 (SCI-Expanded)
- LX. **High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
Leukemia & lymphoma, vol.47, pp.1545-52, 2006 (SCI-Expanded)
- LXI. **Adding a single high-dose chemotherapy cycle to three cycles of standard salvage chemotherapy for relapsed germ-cell tumours does not improve clinical outcomes.**
Oyan B.
Cancer treatment reviews, vol.32, pp.45-9, 2006 (SCI-Expanded)
- LXII. **Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy?**
Oyan B., Koc Y.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.17, pp.349-50, 2006 (SCI-Expanded)
- LXIII. **Prevalence and correlates of metabolic syndrome (MS) in older adults.**
Cankurtaran M., Halil M., Yavuz B., Dagli N., Oyan B., Ariogul S.
Archives of gerontology and geriatrics, vol.42, pp.35-45, 2006 (SCI-Expanded)
- LXIV. **Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis**
Oyan B., Koc Y., Emri S., Kansu E.
MEDICAL ONCOLOGY, vol.23, no.1, pp.125-129, 2006 (SCI-Expanded)
- LXV. **Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-hodgkin lymphoma: A salvage regimen with high response rates before autologous stem cell transplantation**
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.11, no.9, pp.688-697, 2005 (SCI-Expanded)
- LXVI. **IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation**

- Abali H., Oyan B., Koc Y., Kars A., Barista I., ÜNER A., Turker A., Demirkazik F., Tekin F., Tekuzman G., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.28, no.3, pp.264-269, 2005 (SCI-Expanded)
- LXVII. Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase**
Oyan B., Koc Y., Kansu E.
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.81, no.2, pp.155-158, 2005 (SCI-Expanded)
- LXVIII. Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer**
Abali H., Oyan B., Guler N.
CHEMOTHERAPY, vol.51, no.5, pp.280-285, 2005 (SCI-Expanded)
- LXIX. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia**
Koc Y., Oyan B., Kars A., Tekuzman G., Canpinar H., Kansu E.
HEMATOLOGICAL ONCOLOGY, vol.22, no.2, pp.43-53, 2004 (SCI-Expanded)
- LXX. Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?**
Oyan B., Altundag K., Ozisik Y.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.27, no.2, pp.210-211, 2004 (SCI-Expanded)
- LXXI. Thymic malignancy in a breast cancer patient - Is there an association with anti-estrogenic effects of tamoxifen?**
Oyan B., Aksoy S., Yavas O., Kars A., Turker A., Barista I.
ACTA ONCOLOGICA, vol.43, no.1, pp.115-116, 2004 (SCI-Expanded)
- LXXII. Idiopathic fibrosclerosis of bilateral orbits, bilateral ureters, thyroid: a case report and review of the literature.**
Cankurtaran M., Oyan B., Kılıçkap S., Yavuz B., Batman F.
International urology and nephrology, vol.36, pp.495-8, 2004 (SCI-Expanded)
- LXXIII. Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)**
Oyan B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., YALÇIN Ş., Guler N., Koc Y., Kansu E.
ANNALS OF ONCOLOGY, vol.15, pp.153, 2004 (SCI-Expanded)
- LXXIV. Epithelioid sarcoma of vulva - A case report and review of the literature**
Altundag K., Dikbas O., Oyan B., Usubutun A., Turker A.
MEDICAL ONCOLOGY, vol.21, no.4, pp.367-372, 2004 (SCI-Expanded)
- LXXV. Breast cancer and splenic non-Hodgkin's lymphoma, a rare occurrence [1]**
Engin H., Baltali E., Oyan B., Göksel H., Demirel B.
Breast Journal, vol.8, no.6, pp.400-401, 2002 (SCI-Expanded)
- LXXVI. Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer**
Oyan B., Engin H., Yalcin S.
MEDICAL ONCOLOGY, vol.19, no.3, pp.177-179, 2002 (SCI-Expanded)

Articles Published in Other Journals

- I. **Immunotherapy for Lung Cancer**
Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., OYAN ULUÇ B., Yalman D., Yilmaz M. U., Yilmaz Ü., et al.
Journal of Oncological Science, vol.9, no.2, pp.97-111, 2023 (Scopus)
- II. **Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature**
Güldoğan N., Esen İçten G., Tokat F., Tutar B., Kara H., Korkmaz T., Oyan Uluç B., Demir G.

- EUROPEAN JOURNAL OF BREAST HEALTH, vol.17, no.2, pp.200-205, 2021 (ESCI)
- III. Side effects and management: Osteonecrosis of jaw and acute phase reaction**
Oyan B.
Turk Onkoloji Dergisi, vol.36, pp.79-80, 2021 (ESCI)
- IV. Bone-targeted agents used in breast cancer patients with bone metastases**
Oyan B.
Turk Onkoloji Dergisi, vol.36, pp.54-55, 2021 (ESCI)
- V. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**
Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., ERALP Y., Gulluoglu B. M.
TURKISH JOURNAL OF SURGERY, vol.36, no.2, pp.147-163, 2020 (ESCI)
- VI. An unusual cause of arthritis: Carcinoma metastases**
ÖZLER T., SÖNMEZ Ö., EREN O. Ö., DOĞAN EKİCİ A. I., GÜVEN M., ÇAĞATAY U., OYAN ULUÇ B.
Yeditepe Medical Journal , 2014 (Peer-Reviewed Journal)
- VII. Successful allogeneic marrow transplantation from donors with hematologic malignancies**
Koç Y., Oyan B., Akhtar M. S., Schenkein D. P., Miller K. B.
Turkish Journal of Cancer, vol.34, no.3, pp.118-121, 2004 (Scopus)
- VIII. Hematopoietic stem cell transplantation in hematologic malignancies and solid tumors: Hacettepe University Institute of Oncology experience**
Oyan B., Koç Y., Kars A., Türker A., Akyüz C., Güç D., Üner A., Ruacan Ş., Yiğitbaş E., Canpinar H., et al.
Turkish Journal of Cancer, vol.33, no.1, pp.27-39, 2003 (Scopus)
- IX. The prognostic factors for local disease free survival and distant disease free survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamide-adriamycin-5-fluorouracil (CAF) chemotherapy Adjuvan siklofosfamid-adriamisin-5-florourasil (CAF) kemoterapisi alan opere evre I-III meme kanserli hastalarda lokal nükssüz ve uzak nükssüz sağkalimi etkileyen prognostik faktörler**
Oyan B., Güler N., Tekuzman G., Kars A., Türker A., Altundağ M. K., Özışık Y., Baltali E., Çelik I., Hamaloğlu E., et al.
THOD - Turk Hematoloji-Onkoloji Dergisi, vol.12, no.3, pp.115-125, 2002 (Scopus)
- X. The prognostic predictors for disease free survival and overall survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamideadriamycin-5-fluorouracil (CAF) chemotherapy**
Oyan B., Güler N., Kars A., Türker A., Altundağ K., Özışık Y., Baltali E., Çelik I., Barişa I., Güllü I., et al.
Turkish Journal of Cancer, vol.32, no.3, pp.92-104, 2002 (Scopus)

Books

- I. Akciğer kanserinde hedefe yönelik tedavilerde güncel durum**
Oyan Uluç B.
in: Akciğer Kanseri, Meftun Ünsal, Editor, Türkiye Klinikleri Yayınevi, İstanbul, pp.52-58, 2021

Papers Presented at Peer-Reviewed Scientific Conferences

- I. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases**
Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., Karagoz B., Yildirim Y., Karaaslan S., Guler E. N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)
- II. The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey**
Akpamuk U., Hughes R., Swales O., Oyan Uluç B., Kılıçkap S., Demirci U., Sendur M. A., Sonmez Ö., Yazıcı O., Malhan S., et al.
ISPOR 2022, Washington, United States Of America, 15 - 18 May 2022, pp.193, (Summary Text)

- III. Efficacy of regarafenib and 5-Fluorasil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer : A Turkish oncology group study**
Şenocak Taşçı E., Oyan B., Sönmez Ö.
ASCO GI, California, United States Of America, 20 - 22 January 2022, pp.1, (Summary Text)
- IV. Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey**
ŞENDUR M. A. N., Cakar B., Hizal M., Eraslan E., AKSOY S., PAYDAŞ S., Demir N., Sen F., Bulut G., Oruc K., et al.
ESMO Breast Cancer Virtual Congress, ELECTR NETWORK, 5 - 08 May 2021, vol.32, (Summary Text)
- V. Relationship of Vitamin D Receptor Gene Polymorphisms with Adverse Drug Responses In Patients With Colorectal Cancer**
Tosun M., ÇEVİK M., SÖNMEZ Ö., ER Ö., DEMİR O. G., OYAN ULUÇ B., GÜVEN MERT A., DELİORMAN G., KARAALP A., SÜSLEYİCİ DUMAN B.
9th International Molecular Biology and Biotechnology Congress, 6 - 10 December 2020, (Summary Text)
- VI. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey**
Başaran G., Demirci U., Yıldız F., Çiçin İ., Aktaş B. Y., Öztürk B., Sezgin Göksu S., Coşkun H. Ş., Oyan Uluç B., Sönmez Ö., et al.
American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 29 - 31 May 2020, pp.13055, (Summary Text)
- VII. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.**
Basaran G., Demirci U., Yıldız F., Cicin I., Aktas B. Y., Ozturk B., Goksu S. S., Coskun H. S., Oyan B., Sonmez Ö., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38, (Summary Text)
- VIII. Risks and characteristics of early-onset colorectal cancer: A single center retrospective study**
Yazar A., Koç E. S., Tözün A. N., Kutsal N. E., Önder F. O., Aygün C., Oyan Uluç B.
Proceedings of the World Congress of Gastroenterology, İstanbul, Turkey, 21 - 24 September 2019, pp.383, (Summary Text)
- IX. OnkoTürk Kayıt Sistemi: Solid Organ Maligniteli Hastalarda Tedavi ve İzlem Tercihlerinin Belirlenmesine Yönelik Kayıt Çalışması Ara Değerlendirme Sonuçları**
Alan Ö., Yumuk P. F., Dane F., Akgül Babacan N., Coşkun H. Ş., Sezgin Göksu S., Çelik İ., Oyan Uluç B., Yücel İ.
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.292, (Summary Text)
- X. Distribution of ADC-Ki67 with molecular subtypes labels**
Aksoy Özcan Ü., Ulus S., Ekemen S., Oyan Uluç B., Ozcan İ. A.
25th European Congress of Radiology (ECR) 2019, Vienna, Austria, 27 February - 03 March 2019, pp.1, (Summary Text)
- XI. Distribution of ADC-Ki67 with molecular subtypes labels**
ÖZCAN K. Ü., ULUS BUTURAK Ö. S., EKEMEN S., OYAN ULUÇ B., ÖZCAN İ. A.
European Society of Radiology, Viyana, Austria, 27 February - 03 March 2019, (Full Text)
- XII. Correlation of proliferation index markers (Ki-67 and PHH3) with breast MRI apparent diffusion coefficient values**
EKEMEN S., ÖZCAN İ. A., ÖZCAN K. Ü., ULUS BUTURAK Ö. S., OYAN ULUÇ B.
SAN ANTONIO BREAST CANER SYMPOSIUM, San-Antonio, Northern Mariana Islands, 4 - 08 December 2018, vol.79, pp.5, (Full Text)
- XIII. Testing machine learning algorithms' performance for non-invasively identifying breast cancer molecular subtypes using BI-RADS evaluations**
Özcan İ. A., Aksoy Özcan Ü., Ekemen S., Ulus S., Oyan Uluç B.
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5, (Summary Text)

- XIV. Correlation of proliferation index markers (Ki-76 and PHH3) with breast MRI apparent diffusion coefficient values**
Ekemen S., Özcan A., Aksoy Özcan Ü., Ulus S., Oyan Uluç B.
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5, (Summary Text)
- XV. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results**
Esin E., Oksuzoglu O. B. C., Bilici A., ÇIÇİN İ., AKSOY S., Alacacioglu A., Kaplan M. A., ÇABUK D., Sumbul A. T., PAYDAŞ S., et al.
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.104-105, (Summary Text)
- XVI. Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors**
Oyan Uluç B., Sönmez Ö., Yazar A., Teomete M.
American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 1 - 05 June 2018, pp.2436, (Summary Text)
- XVII. TÜRKİYE'DE METASTATİK MEME KANSERİNDE HER2 HEDEFLİTEDAVİDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLİLİKVERİLERİ**
ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., OLGUN P., ŞAKALAR T., AKTAŞ B. Y., DEĞİRMENCİOĞLU S., et al.
7. TÜRK TİBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 24 March 2018, (Summary Text)
- XVIII. Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival**
Oyan B., Eren S., Sonmez Ö., Ozkan F., Yaltirak K., Ture U.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28, (Summary Text)
- XIX. PD-L1 expression of high grade glial tumors at diagnosis and change of expression status at recurrence.**
Oyan B., Eren S., Sonmez Ö., Ozkan F., Yaltirak K., Ture U.
53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35, (Summary Text)
- XX. Immunotherapy releted cardiomyopathy.**
Sonmez Ö., Sever O. N., Oyan B., Demir O. G.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35, (Summary Text)
- XXI. Primary peritoneal hepatoid adenocarcinoma: Response to platin based chemotherapy.**
Oyan B., Sonmez Ö., Eren O. O., Ozkan F., Ozgen A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)
- XXII. The change in the status of MGMT methylation and IDH mutation in initial and recurrent glial tumors and its relation with prognosis.**
Oyan B., Ozturk M. A., Ozkan F., Eren O. O., Sonmez Ö.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
- XXIII. Capecitabine maintenance after first-line induction chemotherapy with docetaxel cisplatin, and fluorouracil in patients with advanced gastric cancer**
Oyan B., Eren O. O., Sonmez Ö.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)
- XXIV. Gallbladder perforation related to bevacizumab in a patient with lung adenocarcinoma.**
Oyan B., Ozturk M. A., Kalayci M.

- 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)
- XXV. The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**
- Ozturk M., Ozaydin S., Oyan B., ÖZBALAK M. M., Arpacı F., Paydas S., Ataergin S., Ferhanoglu B., Kocak N., Gurkan E., et al.
- 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)
- XXVI. Hematopoietic stem cell transplantation for hematological diseases at yeditepe university hospital**
- Yirmibescik S., Senkal V., Kalayci G., Aktas S., Aydin D., Sonmezoglu M., Kocagoz S., Oyan B.
- Tandem BMT Meeting 2007, Colorado, United States Of America, 8 - 12 February 2007, vol.13, pp.94, (Summary Text)
- XXVII. Nephrologic complications in stem cell transplantation**
- Yakupoglu Ü., Uluc B., Koc Y.
- 44th ERA-EDTA Congress, Barcelona, Spain, 22 - 24 June 2007, vol.22, pp.56-57, (Summary Text)
- XXVIII. Tropisetron does not induce arrhythmia in chemo-naive otherwise healthy cancer patients.**
- Abali H., Abali G., Oksuzoglu B., Bakar M., Budakoglu B., Oyan B., Aytemur K., Zengin N.
- 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)
- XXIX. High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL**
- Oyan B., Koc Y., Ozdemir E., Kansu E.
- 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35, (Summary Text)
- XXX. Nonmyeloablative allogeneic stem cell transplantation: Hacettepe University Institute of Oncology Experience.**
- Koc Y., Ozdemir E., Oyan B., Kansu E.
- 46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104, (Summary Text)
- XXXI. High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)**
- Oyan B., Koc Y., Ozdemir E., Kansu E.
- 46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104, (Summary Text)
- XXXII. Granisetron plus alprazolam versus granisetron alone in the control of emesis in patients with operable breast cancer receiving anthracycline containing chemotherapy: A phase III trial.**
- Abali H., Oyan B., Ozisik Y., Guler N.
- 40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
- XXXIII. Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
- Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.
- 40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
- XXXIV. Outcome of well differentiated thyroid cancer: Single institution results.**
- Aksoy S., Abali H., Kilickap S., Yavas O., Oyan B., ELKIRAN E. T., Aras T., Ugurlu O., Guler N., Tekuzman G.
- 40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)
- XXXV. Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-**

myeloablative allogeneic HSCT in patients with multiple myeloma.

Oyan B., Koc Y., Kars A., Turker A., Tekuzman G., Kansu E.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003,
vol.102, (Summary Text)

XXXVI. Primary papillary serous carcinoma of the peritoneum: A retrospective analysis of 13 cases

Oyan Uluç B., Abalı H., Güler N., Kars A., Barışta İ., Tekuzman G.

ASCO Annual Meeting, Illinois, United States Of America, 31 May - 03 June 2003, vol.22, pp.1962, (Summary Text)

XXXVII. High-dose sequential chemotherapy in refractory Hodgkin's and non-Hodgkin's lymphoma.

Oyan B., Koc Y., Kansu E.

44th Annual Meeting of the American-Society-of-Hematology, Pennsylvania, United States Of America, 6 - 10
December 2002, vol.100, (Summary Text)

**XXXVIII. Successful salvage with high-dose sequential chemotherapy coupled with autologous PBSCT and in
vivo purging with Rituximab in patients with primary refractory mantle cell lymphoma presenting in
leukemic phase.**

Oyan B., Koc Y., Tekin F., Kansu E.

44th Annual Meeting of the American-Society-of-Hematology, Pennsylvania, United States Of America, 6 - 10
December 2002, vol.100, (Summary Text)

**XXXIX. IIVP salvage regimen induces high response rates in patients with relapsed FED or NHL prior to
autologous HSCT.**

Abalı H., Koc Y., Oyan B., Tekin F., Tekuzman G., Kansu E.

44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December
2002, vol.100, (Summary Text)

Memberships and Roles in Scientific Organizations

European Society of Medical Oncology, Member, 2004 - Continues, Germany

American Society of Clinical Oncology, Member, 2004 - Continues, United States Of America

Türk Tıbbi Onkoloji Derneği, Member, 2002 - Continues, Turkey

Onkoloji ve İmmunoterapi Derneği, Chairman, 2021 - 2024, Turkey

Onkoloji ve İmmunoterapi Derneği, Vice President, 2018 - 2021, Turkey

Peer Reviews in Scientific Publications

12th International Gastrointestinal Cancers Conference, Conference Paper (Abstract), December 2022

European Journal of Breast Health, Journal Indexed in ESCI, June 2021

Roles in Event Organizations

Aribal M. E., Molinas Mandel N., Bese F. N., Çelik L., Uras C., Oyan Uluç B., 17. Meme Kanserinde Yenilikler Sempozyumu, Scientific Congress, İstanbul, Turkey, January 2025

Arikan A. E., Uras C., Bese F. N., Eralp Y., Aribal M. E., Taşkın F., DÜLGEROĞLU O., OYAN ULUÇ B., YÜCEL S., Breastanbul 2024, Scientific Congress, İstanbul, Turkey, October 2024

Oyan Uluç B., Meme kanser 2024-Güncel tedavi yaklaşımı sempozyumu, Scientific Congress, Ankara, Turkey, May 2024

Oyan Uluç B., 6. Akciğer Kanserinde Güncel Gelişmeler Sempozyumu, Scientific Congress, İstanbul, Turkey, February 2024

Oyan Uluç B., 17. Meme Kanseri Sempozyumu , Scientific Congress, İstanbul, Turkey, February 2024

Molinas Mandel N., Oyan Uluç B., Aribal M. E., Beşe N., Çelik L., Esen İcten G., Uras C., ERALP Y., 16. Meme Kanserinde Yeni Yaklaşımlar, Scientific Congress, İstanbul, Turkey, January 2024

Oyan Uluç B., Vakalarla İnteraktif Onkoloji Toplantısı, Scientific Congress, Sakarya, Turkey, December 2023

Oyan Uluç B., 7. Immunoterapi ve Onkoloji Kongresi , Scientific Congress, Antalya, Turkey, November 2023

Oyan Uluç B., 16. Meme kanseri Atölye çalışmaları, Scientific Congress, İstanbul, Turkey, May 2023

Oyan Uluç B., Genitoüriner Kanserler Sempozyumu, Scientific Congress, Ankara, Turkey, May 2023

Oyan Uluç B., 1. Uluslararası 4. Ulusal Meme Cerrahisi Kongresi, Scientific Congress, Nevşehir, Turkey, May 2023

Oyan Uluç B., Meme Kanseri 2023 Güncel Tedavi Yaklaşımları Sempozyumu, Scientific Congress, İstanbul, Turkey, April 2023

Oyan Uluç B., 5. Akciğer Kanserinde Güncel Gelişmeler Sempozyunu, Scientific Congress, Adana, Turkey, January 2023

Molinas Mandel N., Oyan Uluç B., Uras C., Çelik L., Esen İcten G., Beşe N., Arıbal M. E., Demir G., Yücel A., Çelet Özden B., Meme Kanserinde Yeni Yaklaşımlar, Scientific Congress, İstanbul, Turkey, January 2023

Oyan Uluç B., Vakalarla İnteraktif Onkoloji Toplantısı, Scientific Congress, Sakarya, Turkey, December 2022

Oyan Uluç B., 6. Ulusal Immunoterapi ve Onkoloji Kongresi , Scientific Congress, Antalya, Turkey, October 2022

Taşkin F., Uras C., Güllüoğlu M. B., Arıbal M. E., Oyan Uluç B., Tokat F., Sönmez Ö., Çelik L., Arıkan A. E., Molinas Mandel N., Breastanbul 2022, Scientific Congress, İstanbul, Turkey, October 2022

Oyan Uluç B., Biyobelirteçler ve Onkolojik Tedaviler Sempozyumu 2022, Scientific Congress, İstanbul, Turkey, May 2022

Oyan Uluç B., Meme Kanseri 2022 Güncel Tedavi Yaklaşımları Sempozyumu, Scientific Congress, Adana, Turkey, February 2022

Oyan Uluç B., 2. Ulusal Meme Kanseri Sempozyumu, Scientific Congress, İstanbul, Turkey, February 2022

Oyan Uluç B., 4. Akciğer Kanserinde Güncel Gelişmeler Sempozyumu, Scientific Congress, Ankara, Turkey, January 2022

Molinas Mandel N., Uras C., Oyan Uluç B., Çelik L., Arıbal M. E., Beşe N., Esen İcten G., Meme Kanserinde Yeni Yaklaşımlar, Scientific Congress, İstanbul, Turkey, January 2022

Oyan Uluç B., 5. Ulusal Immunoterapi ve Onkoloji Kongresi, Scientific Congress, Antalya, Turkey, October 2021

Oyan Uluç B., Marmara Onkoloji Derneği 2021/12-13 Haziran Akciğer Sempozyumu, Scientific Congress, İstanbul, Turkey, June 2021

Molinas Mandel N., Oyan Uluç B., Arıbal M. E., Çelik L., Esen İcten G., Beşe N., Uras C., Çelet Özden B., Yücel A., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, January 2021

Uras C., Güllüoğlu M. B., Bese F. N., İcten S. G., Çelik L., Arıbal M. E., Taşkin F., Başaran G., Oyan Uluç B., Sönmez Ö., et al., 4. International breast cancer conference (Breastanbul 2020), Scientific Congress, İstanbul, Turkey, October 2020

Oyan Uluç B., AACR'dan ASCO'ya Onkoloji pratigimize yansiyacaklar kongresi (e-kongre), 13-14 Haziran 2020., Scientific Congress, İstanbul, Turkey, June 2020

Oyan Uluç B., SÖNMEZ Ö., Türk Tıbbi Onkoloji Deneği Meme Tümörleri Kursu, Scientific Congress, İstanbul, Turkey, February 2020

Oyan Uluç B., Meme kanserinde 2020 Güncel Tedavi Yaklaşımları Sempozyumu, Scientific Congress, Ankara, Turkey, February 2020

Arıbal M. E., OYAN ULUÇ B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, January 2020

Oyan Uluç B., Arama Sonuçları 6th congress of MMOF için bulunan akademik makaleler Advances in treatment of biliary atresia - Kasai - Alintulanma sayısı: 45 Web sonuçları 6. Mediterranean Multidisciplinary Oncology Forum Congress, Scientific Congress, Antalya, Turkey, December 2019

Oyan Uluç B., 6th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, Antalya, Turkey, December 2019

Oyan Uluç B., European Hematology Oncology Conference 2019, Scientific Congress, İstanbul, Turkey, October 2019

Oyan Uluç B., 1. Immuno-Onkoloji okulu, Scientific Congress, İstanbul, Turkey, April 2019

Arıbal M. E., Oyan Uluç B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, January 2019

Oyan Uluç B., BREASTANBUL 3rd Breast Cancer Conference, Scientific Congress, İstanbul, Turkey, October 2018

Uras C., Güllüoğlu M. B., Bese F. N., Oyan Uluç B., Korkmaz T., Arıbal M. E., İnce Ü., Tokat F., Yücel S., 4th International breast cancer conference (Breastanbul 2020), Scientific Congress, Turkey, October 2018

Oyan Uluç B., 5th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, İstanbul, Turkey, November 2017

Metrics

Publication: 129
Citation (WoS): 364
Citation (Scopus): 566
H-Index (WoS): 10
H-Index (Scopus): 14

Congress and Symposium Activities

Meme kanserinde güncel yaklaşımalar, Invited Speaker, İstanbul, Turkey, 2024
TAKD Marmara Bölge Toplantısı , Invited Speaker, İstanbul, Turkey, 2024
Akciğer Kanserinde Değişen Standartlar: Erken evreden itibaren immunoterapi ve hedefe yönelik tedaviler, Invited Speaker, İstanbul, Turkey, 2024
On Targed Master Oncology, Invited Speaker, Muğla, Turkey, 2024
Best of ASCO 2024 Annual meeting, Session Moderator, İstanbul, Turkey, 2024
3. Kanserde immuno-onkolojik ve moleküler onkolojik tedaviler kongresi, Moderator, Adana, Turkey, 2024
Meme Kanseri 2024 Güncel tedavi yaklaşımı sempozyumu, Session Moderator, Ankara, Turkey, 2024
11. Tıbbi Onkoloji Kongresi , Invited Speaker, Girne, Cyprus (Kktc), 2024
Meme kanserinde güncel gelişmeler, Invited Speaker, İstanbul, Turkey, 2024
7. Karadeniz Meme kongresi , Invited Speaker, Samsun, Turkey, 2024
UASK 2024 (Uluslararası katılımlı Akciğer Sağlığı Kongresi), Invited Speaker, Antalya, Turkey, 2024
Kanser İmmünoterapisi Derneği (KİD), A'dan Z'ye İmmüno-Onkolojik Tedaviler Kursu, web-tabanlı toplantı , Session Moderator, İstanbul, Turkey, 2024
OİD- Akciğer kanserinde güncel gelişmeler sempozyumu, Session Moderator, İstanbul, Turkey, 2024
4. Meme Kanseri Sempozyumu , Invited Speaker, İstanbul, Turkey, 2024
Onkoloji Diyetisyen Eğitim programı (ONKOBES), Invited Speaker, İstanbul, Turkey, 2024
Long term outcomes of checkpoint inhibitors in NSCLC, Invited Speaker, Manama, Bahrain, 2024
16. Meme kanserinde yeni yaklaşımalar eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2024
17. Ulusal Meme Hastalıkları kongresi , Session Moderator, Ankara, Turkey, 2023
16. Hacettepe Üniversitesi Kanser Enstitüsü Sempozyumu , Invited Speaker, Ankara, Turkey, 2023
II International Baku Breast Cancer Congress, Panelists, Baku, Azerbaijan, 2023
II International Baku Breast Cancer Congress, Invited Speaker, Baku, Azerbaijan, 2023
10.Uluslararası Onkoloji Günleri, Moderator, Muş, Turkey, 2023
ON-TARGED MASTER ONCOLOGY, Invited Speaker, Muğla, Turkey, 2023
TTOD web toplantısı, Invited Speaker, İstanbul, Turkey, 2023
Istanbul Reconstructive Breast Cancer Surgery (IREBS) workshop, Panelists, İstanbul, Turkey, 2023
Istanbul Reconstructive Breast Cancer Surgery (IREBS) workshop, Panelists, İstanbul, Turkey, 2023
OID- Genitoüriner sempozyumu, Session Moderator, Ankara, Turkey, 2023
1. Uluslararası 4. Ulusal Meme Cerrahisi Kongresi, Invited Speaker, Nevşehir, Turkey, 2023
1. Uluslararası 4. Ulusal Meme Cerrahisi Kongresi, Moderator, Nevşehir, Turkey, 2023
WEBTARGED-HR+/HER2- Metastatik Meme Kanserinde Güncel Tedavi Optimizasyonu, Session Moderator, İstanbul, Turkey, 2023
11. Ege Hematoloji Onkoloji Kongresi, Session Moderator, İzmir, Turkey, 2023
6. Karadeniz Meme Kongresi, Panelists, Samsun, Turkey, 2023
Meme Kanserinde Yeni Yaklaşımalar eğitim toplantısı, Panelists, İstanbul, Turkey, 2023
Vakalarla İnteraktif Onkoloji Toplantısı, Moderator, Sakarya, Turkey, 2022
12th International Gastrointestinal Cancers Conference, Session Moderator, İstanbul, Turkey, 2022
BREASTANBUL 2022, Moderator, İstanbul, Turkey, 2022
İstanbul Reconstructive Breast Cancer Surgery (IREBS) workshop , Panelists, İstanbul, Turkey, 2022

Istanbul Reconstructive Breast Cancer Surgery (IREBS) workshop , Panelists, İstanbul, Turkey, 2022
Best of ASCO, Session Moderator, İstanbul, Turkey, 2022
Biyobelirteçler ve Onkolojik Tedaviler sempozyumu 2022, Moderator, İstanbul, Turkey, 2022
5. Gençlerle Onkolojiye Bakış Toplantısı, Panelists, İstanbul, Turkey, 2022
Meme Kanseri 2022 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, İstanbul, Turkey, 2022
WEBTARGETED online toplantı, Session Moderator, İstanbul, Turkey, 2022
11th International Gastrointestinal Cancers Conference (IGICC), Session Moderator, İstanbul, Turkey, 2021
5. Ulusal Ürogenital Kanserler Kongresi, Session Moderator, İstanbul, Turkey, 2021
5. Ulusal İmmunoterapi ve Onkoloji Kongresi, Session Moderator, Antalya, Turkey, 2021
Hedef Kanser 2021 Online kongre, Session Moderator, İstanbul, Turkey, 2021
Onkoloji ve İmmunoterapi Derneği toplantısı, Session Moderator, İstanbul, Turkey, 2021
Meme Kanseri 2021 Güncel Tedavi Yaklaşımları Sempozyumu,, Session Moderator, İstanbul, Turkey, 2021
Marmara Onkoloji Derneği Meme Sempozyumu, Session Moderator, İstanbul, Turkey, 2021